Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$109.43K+1,082%$34.93K+258%$158.7K+3.5%$62.68K$9.26K
$1.14M+203%$2.16M+576%$1.75M+238%$1.3M$375.74K
$1.25M+224%$2.19M+567%$1.91M+184%$1.37M$385K
-$1.25M-224%-$2.19M-567%-$1.91M-184%-$1.37M-$385K
$275.17K+387%$2.47M+42,334%$9.37K+43.1%$126.11K$56.45K
-$970.97K-196%-$1.9M-186%-$328.55K
-$0.03-200%-$0.07-133%-$0.01
-$1.25M-224%-$2.19M-567%-$1.91M-184%-$1.37M-$385K

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Turn Therapeutics Inc. Common Stock profitable?
Turn Therapeutics Inc. Common Stock is not currently profitable: it reported a net loss of $3.5M over the trailing twelve months.
What is Turn Therapeutics Inc. Common Stock's earnings per share?
Turn Therapeutics Inc. Common Stock's diluted EPS over the trailing twelve months is $-0.13.
Where does Turn Therapeutics Inc. Common Stock's income statement data come from?
Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.